311 related articles for article (PubMed ID: 34599021)
1. Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer.
Liu H; Bai L; Huang L; Ning N; Li L; Li Y; Dong X; Du Q; Xia M; Chen Y; Zhao L; Li Y; Meng Q; Wang J; Duan Y; Ming J; Yuan AQ; Yang XP
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599021
[TBL] [Abstract][Full Text] [Related]
2. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer.
Yi M; Wu Y; Niu M; Zhu S; Zhang J; Yan Y; Zhou P; Dai Z; Wu K
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460337
[TBL] [Abstract][Full Text] [Related]
3. A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer.
Del Bano J; Florès-Florès R; Josselin E; Goubard A; Ganier L; Castellano R; Chames P; Baty D; Kerfelec B
Front Immunol; 2019; 10():1593. PubMed ID: 31354732
[TBL] [Abstract][Full Text] [Related]
4. Bispecific Antibodies for Triple Negative Breast Cancer.
Dees S; Ganesan R; Singh S; Grewal IS
Trends Cancer; 2021 Feb; 7(2):162-173. PubMed ID: 33041246
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
[TBL] [Abstract][Full Text] [Related]
6. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
Desroys du Roure P; Lajoie L; Mallavialle A; Alcaraz LB; Mansouri H; Fenou L; Garambois V; Rubio L; David T; Coenon L; Boissière-Michot F; Chateau MC; Ngo G; Jarlier M; Villalba M; Martineau P; Laurent-Matha V; Roger P; Guiu S; Chardès T; Gros L; Liaudet-Coopman E
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290768
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells.
Chang CH; Wang Y; Li R; Rossi DL; Liu D; Rossi EA; Cardillo TM; Goldenberg DM
Cancer Res; 2017 Oct; 77(19):5384-5394. PubMed ID: 28819027
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer.
Lum LG; Al-Kadhimi Z; Deol A; Kondadasula V; Schalk D; Tomashewski E; Steele P; Fields K; Giroux M; Liu Q; Flaherty L; Simon M; Thakur A
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34117114
[TBL] [Abstract][Full Text] [Related]
9. Construction of a novel TROP2/CD3 bispecific antibody with potent antitumor activity and reduced induction of Th1 cytokines.
Wang D; Zhang L; Wang B; Zhao L; Deng L; Xu W; Huang H
Protein Expr Purif; 2023 May; 205():106242. PubMed ID: 36746324
[TBL] [Abstract][Full Text] [Related]
10. A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer.
Zhou Y; Zong H; Han L; Xie Y; Jiang H; Gilly J; Zhang B; Lu H; Chen J; Sun R; Pan Z; Zhu J
J Exp Clin Cancer Res; 2020 May; 39(1):87. PubMed ID: 32398042
[TBL] [Abstract][Full Text] [Related]
11. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
12. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
13. A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune.
Jiang Z; Cai G; Liu H; Liu L; Huang R; Nie X; Gui R; Li J; Ma J; Cao K; Luo Y
J Nanobiotechnology; 2024 May; 22(1):296. PubMed ID: 38811964
[TBL] [Abstract][Full Text] [Related]
14. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106
[TBL] [Abstract][Full Text] [Related]
15. Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines.
Kubo M; Umebayashi M; Kurata K; Mori H; Kai M; Onishi H; Katano M; Nakamura M; Morisaki T
Anticancer Res; 2018 Jul; 38(7):4273-4279. PubMed ID: 29970561
[TBL] [Abstract][Full Text] [Related]
16. TrMab-6 Exerts Antitumor Activity in Mouse Xenograft Models of Breast Cancers.
Tanaka T; Ohishi T; Saito M; Kawada M; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2022 Feb; 41(1):32-38. PubMed ID: 35225665
[TBL] [Abstract][Full Text] [Related]
17. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
18. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
19. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
Wang X; Osada T; Wang Y; Yu L; Sakakura K; Katayama A; McCarthy JB; Brufsky A; Chivukula M; Khoury T; Hsu DS; Barry WT; Lyerly HK; Clay TM; Ferrone S
J Natl Cancer Inst; 2010 Oct; 102(19):1496-512. PubMed ID: 20852124
[TBL] [Abstract][Full Text] [Related]
20. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
Groeneveldt C; Kinderman P; van den Wollenberg DJM; van den Oever RL; Middelburg J; Mustafa DAM; Hoeben RC; van der Burg SH; van Hall T; van Montfoort N
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
